22.50 USD
▲+0.11+0.49%
盘后 22.55 +0.22%
2026-11-19
市值
$454.39M
市盈率
—
EPS
-0.60
股息率
—
52 周区间
19.20 – 39.71
成交量
268.43K
Beta
1.23
目标价
51.20
52W 低 19.2052W 高 39.71
价格走势
公司简介
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g...